A BLA has been filed for bentracimab and, if approved, has the potential to be the first therapy to reverse the effects of ...
A drug developed as an antidote to the antiplatelet agent ticagrelor safely and effectively reversed ticagrelor's ...
An investigational monoclonal antibody called bentracimab can safely and effectively reverse potentially catastrophic ...
Q4 2024 Earnings Conference Call March 31, 2025 4:30 PM ETCompany ParticipantsAdanna Alexander – IRPhillip Chan - ...
Current guidelines favouring ticagrelor over clopidogrel might take this new evidence ... prior intolerance to either drug, recent (< 30 d) previous hospital admission for acute coronary syndrome, and ...
Cytosorbents Corporation (CTSO) reports 25% Q4 revenue growth, strong margins, and updates on FDA-reviewed DrugSorb-ATR launch.
A step forward in de-escalating treatment The evolution of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) has been shaped by the continuous challenge of balancing ...
News-Medical.Net on MSN6d
Research reveals optimal duration of dual antiplatelet therapy after stent implantationPatients who have a stent implanted to open a blocked coronary artery face dual risks of developing blood clots and of having ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback